Serial Monitoring of Immune Markers Being Represented Regulatory T Cell/T Helper 17 Cell Ratio: Indicating Tolerance for Tapering Immunosuppression after Liver Transplantation by Jhun, JooYeon et al.
Serial Monitoring of Immune Markers
Being Represented Regulatory T Cell/T
Helper 17 Cell Ratio: Indicating Tolerance
for Tapering Immunosuppression
after Liver Transplantation
The Harvard community has made this
article openly available.  Please share  how
this access benefits you. Your story matters
Citation Jhun, J., S. H. Lee, S. K. Lee, H. Y. Kim, E. S. Jung, D. G. Kim,
J. Choi, et al. 2018. “Serial Monitoring of Immune Markers
Being Represented Regulatory T Cell/T Helper 17 Cell Ratio:
Indicating Tolerance for Tapering Immunosuppression after Liver
Transplantation.” Frontiers in Immunology 9 (1): 352. doi:10.3389/
fimmu.2018.00352. http://dx.doi.org/10.3389/fimmu.2018.00352.
Published Version doi:10.3389/fimmu.2018.00352
Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:35981965
Terms of Use This article was downloaded from Harvard University’s DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at http://
nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAA
March 2018 | Volume 9 | Article 3521
Original research
published: 01 March 2018
doi: 10.3389/fimmu.2018.00352
Frontiers in Immunology | www.frontiersin.org
Edited by: 
Duncan Howie, 
University of Oxford, 
United Kingdom
Reviewed by: 
Alberto Baroja-Mazo, 
Instituto Murciano de 
Investigación Biosanitaria, Spain 
Nick David Jones, 
University of Birmingham, 
United Kingdom
*Correspondence:
Mi-La Cho 
iammila@catholic.ac.kr; 
Jong Young Choi 
jychoi@catholic.ac.kr
†These authors have contributed 
equally to this study.
Specialty section: 
This article was submitted 
to Immunological 
Tolerance and Regulation, 
a section of the journal 
Frontiers in Immunology
Received: 23 November 2017
Accepted: 07 February 2018
Published: 01 March 2018
Citation: 
Jhun J, Lee SH, Lee SK, Kim HY, 
Jung ES, Kim DG, Choi J, Bae SH, 
Yoon SK, Chung BH, Yang CW, 
Cho M-L and Choi JY (2018) Serial 
Monitoring of Immune 
Markers Being Represented 
Regulatory T Cell/T Helper 17 
Cell Ratio: Indicating Tolerance 
for Tapering Immunosuppression 
after Liver Transplantation. 
Front. Immunol. 9:352. 
doi: 10.3389/fimmu.2018.00352
serial Monitoring of immune  
Markers Being represented 
regulatory T cell/T helper 17 cell 
ratio: indicating Tolerance for 
Tapering immunosuppression  
after liver Transplantation
JooYeon Jhun1†, Seung Hoon Lee1,2†, Soon Kyu Lee3†, Hee Yeon Kim3, Eun Sun Jung4,  
Dong Goo Kim5, JeongWon Choi1, Si Hyun Bae3, Seung Kew Yoon3, Byung Ha Chung6, 
Chul Woo Yang6, Mi-La Cho1* and Jong Young Choi3*
1 The Rheumatism Research Center, Catholic Research Institute of Medical Science, Seoul, South Korea, 2 Division of 
Immunology, Department of Microbiology and Immunobiology, Harvard Medical School, Boston, MA, United States, 
3 Division of Hepatology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic 
University of Korea, Seoul, South Korea, 4 Department of Pathology, Seoul St. Mary’s Hospital, College of Medicine, The 
Catholic University of Korea, Seoul, South Korea, 5 Department of Surgery, Seoul St. Mary’s Hospital, College of Medicine, 
The Catholic University of Korea, Seoul, South Korea, 6 Convergent Research Consortium for Immunologic Disease, Seoul 
St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea
Recipients of liver transplantation (LT) require long-term immunosuppressive drug treat-
ment, but lifelong immunosuppressive treatment has severe side effects. It is known that 
some LT recipients develop immune tolerance, and although the development of such 
operational tolerance should allow a decrease in the burden of immunosuppressive drug 
treatment, the factors that indicate operational tolerance are not clear. This study aimed 
to monitor immunological markers over time in LT recipients to identify those markers 
indicating the development of operational tolerance. We performed a prospective pilot 
study measuring immune markers, including the ratio of regulatory T (Treg) and T helper 
(Th) 17 cells in peripheral blood in the 14 most immunologically stable patients among 70 
clinically stable LT recipients. The doses of immunosuppressive drugs given to these 14 
LT recipients were tapered over time and they were monitored for immunological markers 
related to the development of immune tolerance. As the doses of immunosuppressive 
drugs were reduced, the Treg/Th17, Th1/Th17, and CD8/Th17 ratio in tolerant recipients 
was significantly increased compared with that of nontolerant recipients. These results 
suggest that monitoring of changes in the immune makers, including Treg/Th17 ratio 
during tapering of immunosuppression may allow prediction of the development of 
tolerance.
Keywords: regulatory T cell, T helper 17 cell, liver transplantation, tolerance, immunosuppression
Abbreviations: Treg, regulatory T cell; Th17, T helper 17 cell; LT, liver transplantation; IL, interleukin; HBV, hepatitis B virus; 
HCV, hepatitis C virus.
Figure 1 | Schematic timeline of tapering IS and follow-up, including 
transplant clinic visit and laboratory test.
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inTrODucTiOn
Liver transplantation (LT) has a lower rate of rejection than trans-
plantation of other solid organs. Indeed, operational tolerance has 
been reported to occur in approximately 5% of LT recipients, with 
the most optimistic study reporting up to 50% (1–3). Although 
there have been many studies of immune tolerance after LT that 
have used different inclusion criteria to identify clinically stable 
patients (4–6), there is no clinically useful indicator that predicts 
tolerance. A recent study suggested that immune tolerance after 
LT is associated with time after surgery (>10 years) (7). Because 
LT recipients are given long-term immunosuppression, it is likely 
that undesirable side effects of immunosuppressive drug treat-
ment occur in LT recipients who may actually be tolerant. Thus, 
there is a requirement to define immune markers in peripheral 
blood that can identify those LT recipients who will develop 
tolerance, especially during tapering of immunosuppressive drug 
treatment.
Immune monitoring after LT using biomarkers is an impor-
tant method for identifying rejection and immune tolerance. 
There is evidence that the levels of inflammatory cytokines, 
such as tumor necrosis factor-α and interleukin (IL)-6 are 
biomarkers of rejection after LT (8, 9). Since, T helper 17 
(Th17) cells cause chronic and excessive inflammation (10, 11), 
Th17 cells also play a critical role in the prognosis of LT. It is 
well known that Th17 cells induce liver allograft rejection in a 
rat model (12), while LT recipients experiencing acute rejection 
had significantly increased peripheral blood Th17  cells com-
pared with LT recipients without rejection (13). The population 
of CD4+IL-17+ T helper (Th17) cells in peripheral blood has 
been reported to be increased in LT recipients experiencing 
rejection compared to those without rejection (13). Moreover, 
the differentiation of Th17  cells in peripheral blood was cor-
related positively with the histological score of liver tissue in 
LT recipients experiencing rejection (14). In contrast, T regula-
tory (Treg) cells have immunosuppressive activity and can 
reduce inflammatory responses (15). Numerous studies have 
demonstrated the anti-inflammatory function of Treg cells and 
their ability to enhance LT tolerance (16–18). It is also well 
documented that the levels of circulating CD4+CD25highFoxP3+ 
Treg cells were downregulated in LT patients undergoing rejec-
tion and were negatively correlated with rejection severity (19). 
Indeed, CD4+CD25high Treg cells perform a significant role in 
maintaining tolerance (20).
Previously, we demonstrated an imbalance between Th17 and 
Treg cells in peripheral blood mononuclear cells (PBMCs) from 
LT recipients (21); immunosuppressive treatment had no signifi-
cant effect on Th17 cells, but significantly reduced the frequency 
of Treg cells. Therefore, we designed this study to undertake 
long-term monitoring of LT recipients. Based on the overall func-
tion of Th17 and Treg cells in LT and in immune inflammatory 
responses, we hypothesized that the frequencies of Th17 and Treg 
cells in the peripheral blood of LT recipients could be an indicator 
of LT prognosis. We sought to demonstrate whether the Treg/
Th17 ratio in peripheral blood of LT recipients was positively cor-
related with the development of tolerance and whether it could be 
an effective diagnostic marker of LT tolerance.
PaTienTs anD MeThODs
Patients
For this study, patients were prospectively enrolled from a single 
LT clinic at Seoul St. Mary’s Hospital. The inclusion criteria were: 
liver transplanted more than 3 years ago; a high level of liver func-
tion with no history of rejection; no history of significant change 
in the dosage of immunosuppressive drugs for at least 1  year; 
age ≥20  years and ≤65  years; Eastern Cooperative Oncology 
Group performance score 0–1; Child–Pugh score A; and patients 
agreed to participate. Exclusion criteria were: hepatitis C virus 
positive; a history of biliary complications or infection; other 
severe medical comorbidities; or a history of malignancy. Patients 
who met the inclusion criteria were examined for immunologic 
markers, including Treg cells (CD4, CD25, and Foxp3), Th17 cells 
(CD4, IL-17), and various cytokines [IL-4, IL-10, IL-17, IL-33, 
and interferon (IFN)-γ]. The 20% most immunologically stable 
patients were finally included as the tapering group. Informed 
and written consent was provided by all patients and the study 
was approved by the Institutional Review Board of Seoul St. 
Mary’s Hospital (KC11SISI0340).
Tapering Protocol
Schematic timeline of tapering immunosuppressant is shown in 
Figure 1. Enrolled patients were followed up every 3 months if 
possible. At every visit, laboratory tests including those for liver 
function, routine blood counts, and immunologic markers were 
performed. The doses of immunosuppressive agents were reduced 
by 25–30% every 6 months until they reached half the recom-
mended dose. From half-dose to discontinuation, the doses were 
tapered more cautiously and slowly by 10–12.5% every 6 months 
depending on the patient’s clinical status. The target time to 
discontinuation of immunosuppressive drug treatment was 
30–36 months. After 1 year from stopping immunosuppression, 
liver biopsy was performed in consented tolerant patients.
Definition of nontolerance and 
Operational Tolerance
During tapering of the doses of immunosuppressive drugs, 
an increase in aspartate aminotransferase (AST) or alanine 
aminotransferase (ALT) levels to greater than or equal to twice 
the upper baseline value without any other cause, such as infec-
tion, drugs, or biliary complications was considered to indicate 
nontolerance/rejection. If the patients agreed, a liver biopsy was 
performed to confirm nontolerance by histology. Operational 
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tolerance was defined as having continuously stable liver function 
tests for 12 months after discontinuation of immunosuppressive 
drugs.
PBMc isolation and Flow cytometric 
analysis
Peripheral blood mononuclear cells were isolated from heparin-
ized venous blood by standard density gradient centrifugation 
over Ficoll-Paque (GE Healthcare Biosciences, Uppsala, Sweden). 
Cell cultures were performed in RPMI-1640 medium (Gibco 
BRL, Carlsbad, CA, USA) containing penicillin (100  U/mL), 
streptomycin (100 µg/mL), and 10% fetal bovine serum (Gibco 
BRL) that had been inactivated by heating to 55°C for 30 min. 
The cell suspensions were dispensed into 48-well plates (Nunc, 
Roskilde, Denmark).
Preparation of PBMCs for flow cytometric analysis was 
completed within 1  h after the sampling of peripheral blood. 
For analysis of intracellular cytokine production, PBMCs were 
stimulated with 50  ng/mL phorbol myristate acetate (Sigma 
Aldrich, St. Louis, MO, USA), 500  ng/mL ionomycin (Sigma 
Aldrich), and GolgiStop (BD Biosciences, San Diego, CA, USA) 
for 4 h. The cells were then washed and 5 × 105 cells per sample 
were incubated with antibodies against surface markers for 
30  min at 4°C in the dark. The cells were then permeabilized 
using a Cytofix/Cytoperm Plus kit (BD Biosciences) and stained 
with antibodies specific for intracellular markers for 30 min at 
4°C in the dark. For analysis of Treg cells, PBMCs were surface-
labeled with phycoerythrin (PE)/cyanine 7-conjugated anti-CD4 
(BioLegend, San Diego, CA, USA) and allophycocyanin (APC)-
conjugated anti-CD25, followed by fixation, permeabilization, 
and intracellular staining with anti-Foxp3, performed using 
the eBioscience Foxp3 staining kit (eBioscience, San Diego, 
CA, USA). For intracellular staining, PE-conjugated anti-IL-17 
(BD Biosciences), FITC-conjugated anti-IFN-γ (eBioscience), 
and APC-conjugated anti-IL-4 (BD Biosciences) were used. 
Appropriate isotype controls were used to set gates for analysis 
of cytokine expression. Cells were analyzed using a FACSCalibur 
flow cytometry system (BD Biosciences) and FlowJo software 
(Tree Star, Ashland, OR, USA).
enzyme-linked immunosorbent  
assays for cytokines
In brief, a 96-well plate (Nunc) was coated with 4 µg/mL mono-
clonal antibody against IL-4, IL-10, IL-17, IL-21, IL-33, or IFN-γ 
(R&D Systems) at 4°C overnight. After blocking with phosphate-
buffered saline (PBS)/1% bovine serum albumin/0.05% Tween 
20 (PBS/Tween) for 2  h at room temperature (22–25°C), test 
samples and the standard recombinant IL-4, IL-10, IL-17, IL-21, 
IL-33, and IFN-γ were added to the 96-well plate and incubated 
for 2 h at room temperature. Plates were washed four times with 
PBS/Tween and then incubated with 500  ng/mL biotinylated 
mouse monoclonal antibodies against IL-4, IL-10, IL-17, 
IL-21, IL-33, and IFN-γ for 2 h at room temperature. After wash-
ing, streptavidin-alkaline phosphatase-horseradish peroxidase 
conjugate (Sigma) was added and the plate was incubated for 
2 h. The plate was again washed and incubated with 1 mg/mL 
p-nitrophenyl phosphate (Sigma) dissolved in diethanolamine 
(Sigma) to develop the color reaction. The reaction was stopped 
by the addition of 1 M NaOH and the optical density of each 
well was read at 405 nm. The lower limit of detection for recom-
binant IL-4, IL-10, IL-17, IL-21, IL-33, and IFN-γ was 10  pg/
mL. Recombinant human IL-4, IL-10, IL-17, IL-21, IL-33, and 
IFN-γ diluted in culture medium were used as the calibration 
standards at concentrations in the range of 10–2000  pg/mL. 
A standard curve was drawn by plotting optical density against 
the log of the concentration of recombinant cytokines and was 
used to calculate the IL-4, IL-10, IL-17, IL-21, IL-33, and IFN-γ 
concentrations in the test samples.
hematoxylin–eosin staining and 
immunohistochemistry
Liver needle biopsies were performed and the tissue was fixed in 
4% (vol/vol) paraformaldehyde and embedded in paraffin. The 
sections were dewaxed using xylene and dehydrated in a gradi-
ent of alcohols. Liver tissue sections (5 µm thick) were stained 
with hematoxylin and eosin and monoclonal antibodies to 
human IL-17 (Abcam, Cambridge, UK) and Foxp3 (Santa Cruz 
Biotechnology, Santa Cruz, CA, USA). Immunohistochemistry 
was performed using the Vectastain ABC kit (Vector Laboratories, 
Burlingame, CA, USA). Tissues were incubated first with the 
primary anti-IL-17 and anti-Foxp3 antibodies overnight at 4°C, 
followed by incubation with a biotinylated secondary linking Ab 
and a streptavidin-peroxidase complex for 1 h. The final color 
product was developed using diaminobenzidine chromogen 
(Dako, Carpinteria, CA, USA). The sections were counter-
stained with hematoxylin and photographed with an Olympus 
photomicroscope (Tokyo, Japan).
statistical analysis
The characteristics of patients are presented as the mean ± SD 
(range) or numbers, as appropriate. Spearman correlation analy-
sis was performed to identify relationships between drug dosage 
and the Treg/Th17 ratio. To evaluate the differences between 
the regulation and non-regulation groups, repeated-measures 
analysis of variance was used. Comparison of continuous 
baseline characteristics and immunologic markers between 
the regulation and non-regulation groups were analyzed by 
Student’s t-test for normally distributed variables and the 
Mann–Whitney U test for nonnormally distributed variables. 
Categorical variables were evaluated using the chi-square test 
with Fisher’s exact test. All statistical analyses were performed 
using SPSS ver. 15.0 (SPSS, Chicago, IL, USA).
resulTs
selection of lT recipients for Tapering
A total of 194 patients were enrolled in this study. Of these, 109 
were excluded for criteria, including a history of biliary compli-
cations (n = 70), a history of rejection (n = 10), or malignancy 
(n =  4). Of the 85 patients eligible for inclusion, 70 agreed to 
participate in this study (Figure 2A). The baseline characteristics 
of these 70 patients are shown in Table 1. They comprised 53 men 
Figure 2 | Study flow chart and selection of tapering patients based on difference of cytokines and T cell populations of patients (n = 70). Heat map of T cell 
differentiation and cytokine expression data from peripheral blood mononuclear cells (PBMC) samples of patients undergoing tapering (n = 14) and those not 
undergoing tapering (n = 56). The legend on the horizontal line indicates the number of patients involved in the investigation. (a) Flow chart of patients included  
in the study. LT, liver transplantation; HBV, hepatitis B virus; HCV, hepatitis C virus. (B) ELISA of patient plasma was performed to identify cytokines that were 
differentially expressed between the two groups. (c,D) Flow cytometry of patient PBMCs was performed to evaluate whether T helper (Th1), Th2, Th17 cell,  
and regulatory T cells differed between the two groups. The expression of cytokines (pg/mL) and differentiation of cells (%) are illustrated according to the  
color scale on the left. Red indicates high expression and black indicates low expression.
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and 17 women with a mean age of 57.7 ± 8.3 (35–71) years. The 
most common reason for LT was liver cirrhosis caused by hepa-
titis B (n = 35), and the time, since LT was 85.1 ± 28.6 (41–181) 
months. Fifty of the patients (71.5%) took tacrolimus (n = 30) 
or cyclosporine (n = 20) for immunosuppression. We analyzed 
the immunological markers in the PBMCs and plasma from all 
these LT recipients. Based on low expression of proinflammatory 
cytokines, Th17 and high expression of Treg, we identified the 
14 most immunologically stable patients who were included as 
the tapering group (Figures 2B,C). The levels of Th1, Th2, and 
regulatory B cells were similar in the tapering and nontapering 
groups (Figure 2D).
Baseline characteristics and clinical 
results of the Tapering group
The tapering group, which consisted of 14 immunologically 
stable patients, was treated with tapering doses of immunosup-
pressive drugs. The clinical information for these LT recipients is 
TaBle 2 | Characteristics at the time of rejection in patients undergoing tapering 
(n = 7).
Variable
Intolerant (number) 7 (50%)
Dosage of IS 29.0 ± 17.6% (0–50%)
Peak AST/ALT 86.1 ± 45.4 (41–164)/145.4 ± 84.4 
(51–258)
Liver biopsy 4/7 (57.2%)
RAI score 3.25 ± 1.3 (2–5)
immune markers  
(% of initial value)
Treg/T helper 17 cell (Th17) 210.1 ± 84.8 (136–364)
T regulatory cell (Treg) 146.9 ± 45.6 (69–214)
Th17 68.0 ± 25.4 (32–102)
Th1 81.4 ± 26.6 (40–108)
CD8+EM/interferon (IFN)-γ 86.5 ± 34.8 (42–138)
CD8+CM/IFN-γ 80.8 ± 37.4 (38–148)
result after rejection
Recovery 7/7 (100%)
Dose reduction retrial 5/7 (57.2%)
Rejection after retrial 0/5 (0%)
Dosage of IS after retrial 41.0 ± 26.1 (10–75%)
IS, immunosuppressant; AST, asparate aminotransferase; ALT, alanine 
aminotransferase; RAI, rejection activity score; AP, alkaline phosphatase; GGP, gamma-
glutamyl transpeptidase.
TaBle 1 | Baseline characteristics of patients (n = 70).
Variable
Age (years) 57.7 ± 8.3 (35–71)
Sex (M/F) 53 (75.7%)/17 (24.3%)
LDLT/DDLT 54 (77.1%)/16 (22.9%)
Time since LT (months) 85.1 ± 28.6 (41–181)
Type of immunosuppression
Tacrolimus 30 (42.9%)
Cyclosporine 20 (28.6%)
MMF 1 (1.4%)
Tacrolimus + MMF 4 (5.7%)
Cyclosporine + MMF 10 (14.3%)
Other (changed because of side effects) 5 (7.1%)
reason for lT
LC-B 35 (50.0%)
Alcohol 5 (7.1%)
Hepatocellular carcinoma 23 (32.9%)
Combined 7 (10.0%)
LDLT, living donor liver transplantation; DDLT, deceased donor liver transplantation; 
LT, liver transplantation; MMF, mycophenolate mofetil; LC-B, liver cirrhosis caused by 
hepatitis B.
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documented in Table S1 in Supplementary Material. They were 
initially being treated with tacrolimus (n =  7) or cyclosporine 
(n =  7). The mean duration of tapering to 50% of the initial 
immunosuppressive drug dose was 11.3 ±  2.1 (8–15) months 
and the mean time to discontinuation (0% dose) was 32.8 ± 3.2 
(30–36) months. The mean tapered dose of immunosuppression 
(% of initial dose) was 23.4 ± 21.3% (0–75%).
Of the 14 tapering group patients, 7 (50%) had been stable 
during minimization and/or stopping immunosuppression in the 
study. These seven patients were named as regulation group and 
the group subclassified into two groups: tolerance group (group 1, 
n = 3), patients who were able to discontinue and maintain without 
immunosuppressive drug treatment; minimization group (group 
2, n = 4), patients who achieved 70% (n = 2) or 80% (n = 2) reduc-
tion in the dose of immunosuppressive drugs. The other seven 
patients had experienced rejection during tapering period and 
were named as non-regulation group. All non-regulation group 
(n = 7) patients were successfully recovered from nontolerance 
after increasing dose of immunosuppression. After recovering 
from nontolerance, five patients could be re-tapered to the dose 
right before the rejection occurred and the other two were not re-
tapered. According to re-tapering or not, non-regulation group 
were subclassified into two groups: re-tapering group (group 3, 
n = 5), no re-tapering group (group 4, n = 2).
At the time that rejection occurred in the non-regulation group, 
the mean dosage of immunosuppressive drugs was 29.0 ± 17.6% 
(0–50%) of the initial dosage (Figure S1 in Supplementary 
Material; Table 2). Peak AST and ALT levels were 86.1 ±  45.4 
(41–164) and 145.4 ±  84.4 (51–258), respectively. Four of the 
non-regulation group underwent liver biopsy and the mean 
rejection activity score was 3.25 ± 1.3 (2–5).
A comparison of the baseline characteristics of the regulation 
and non-regulation groups showed no significant differences in 
age, sex, type of LT, type of immunosuppressant, or reason for 
LT (Table 3). Although the difference with other groups was not 
significant, the group 4 patients were younger (51.0 ± 11.3 years) 
and had a shorter follow-up after LT (43.5 ± 0.7 months).
Failure to increasing of the Treg/Th17 
ratio can Be used to Predict 
nontolerance of Drug Tapering
During tapering immunosuppressive drugs, we checked the level 
of immune markers and calculated the ratio in each dosage of 
immunosuppressive drugs. The ratio at the 100% dosage was 
defined as the reference point (1.0) and the other ratios in each 
dosage were converted according to the reference point. As the 
doses of immunosuppressive drugs were tapered, the Treg/Th17 
ratio increased significantly for the tapering group as a whole 
(ρ = 0.586, P < 0.005, Figure 3A). In the regulation group, the 
Treg/Th17 ratio remained increased at doses tapered to 75 and 50% 
of the initial dose. In contrast, in the non-regulation group, the 
Treg/Th17 ratio at 50% dosage was higher than that at 100% dos-
age, but lower than that at 75% dosage (Figure 3B). Comparison 
of the Treg/Th17 ratios in the regulation and non-regulation 
groups showed that those in the non-regulation group did not 
increase as much as those in the regulation group (P < 0.001). 
At the time when the immunosuppression dose was 50% of the 
initial dose, the Treg/Th17 ratio differed significantly between the 
regulation and non-regulation groups (P = 0.025, Figure 3C). In 
the regulation group, as tapering immunosuppressive drugs, both 
tolerance group (group 1) and minimization group (group 2) had 
increased Treg/Th17 ratio with much higher ratio in group 1 than 
that in group 2 (Figure 3D). When all groups were compared, 
the Treg/Th17 ratio in group 1 was increased compared to those 
of the other three groups (Figure 3E). At the time when the dose 
TaBle 3 | Comparison of baseline characteristics in tolerant and nontolerant groups.
Variable regulation group (n = 7) non-regulation group (n = 7) P value
group 1 (n = 3) group 2 (n = 4) group 3 (n = 5) group 4 
(n = 2)
Age (years) 59.7 ± 13.3 57.3 ± 12.3 61.8 ± 10.3 51.0 ± 11.3 0.60
Sex (M/F) 3/0 4/0 5/0 2/0 1.00
LDLT/DDLT 2/1 2/2 1/1 4/1 0.94
Time since LT (months) 72.3 ± 25.5 84.5 ± 29.9 94.6 ± 51.4 43.5 ± 0.7  0.17
Type of immunosuppression 0.50
Tacrolimus 1 2 3 1
Cyclosporine 2 2 2 1
Reason for LT 0.89
LC-B 1 3 2 1
Alcohol 1 0 1 0
HCC 1 0 1 0
Combined 0 1 1 1
LDLT, living donor liver transplantation; DDLT, deceased donor liver transplantation; LT, liver transplantation; LC, liver cirrhosis caused by hepatitis B; HCC, hepatocellular carcinoma.
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was 50% of the initial dose, the increase in Treg/Th17 ratio was 
greatest in group 1, followed by group 2, group 3, and group 4 
(Figure 3F).
Variation in Th1/Th17, cD8+eMiFn-γ+/ 
Th17, and cD8+cMiFn-γ+/Th17 May Be  
an indicator of nontolerance during  
Drug Tapering
We also analyzed the variation in Th1/Th17, CD8+ effector 
memory (CD8+EM)IFN-γ+/Th17, and CD8+ central memory 
(CD8+CM)IFN-γ+/Th17 ratios as the immunosuppressive drug 
doses were tapered to half the initial dose.
Comparison of the changes in the Th1/Th17 ratio showed it 
was dramatically increased in the regulation group compared 
to the non-regulation group, similar to the Treg/Th17 ratio 
(Figure 4A). At the time of 50% of the initial dose, the Th1/Th17 
ratio was significantly higher in the regulation group (P = 0.038, 
Figure 4B), and a four-group comparison showed that the Th1/
Th17 ratio increased much more in group 1 than in the other 
three groups (Figure S2A in Supplementary Material). The differ-
ence in the ratio did not reach significance at the 75% dose, but 
group 1 demonstrated a significantly higher ratio than the other 
three groups at the 50% dose, at which point the magnitude of 
the ratio decreased from group 2 to group 3, but did not differ 
significantly (Figure S2B in Supplementary Material). In group 
4, the ratio was actually decreased compared with the ratio at the 
initial dose.
The regulation group demonstrated a higher CD8EM+IFN-γ+/
Th17 ratio than the non-regulation group during the tapering of 
immunosuppressive drug dose (Figure 4C). The CD8+EMIFN-γ+/
Th17 ratio was higher in the regulation group at 50% dosage, but 
this increase was not significant (P = 0.259, Figure 4D). In the 
four-group analysis, the ratios of CD8+EMIFN-γ+/Th17 decreased 
in order from group 1 to group 2, group 3, and group 4. In group 
1, the CD8+EMIFN-γ+/Th17 ratio increased more than in the other 
three groups. However, in group 4, the ratio consistently decreased 
from the initial ratio (Figures S2C,D in Supplementary Material). 
Similarly to other markers, the CD8+CMIFN-γ+/Th17 ratio was 
higher in the regulation group than in the non-regulation group, 
especially at 50% dosage (Figures 4E,F). Subgroup analysis which 
showed the ratio in group 1 was much higher than those in the 
other groups, which did not differ significantly (Figures S2E,F in 
Supplementary Material).
alteration of immune Markers during 
Tapering to 0% (Discontinuation of 
Treatment)
During tapering of immunosuppression, the Th1/Th17, CD8+EM 
IFN-γ+/Th17, and CD8+CMIFN-γ+/Th17 ratios all increased. The 
Th1/Th17 (Figure S3A in Supplementary Material), CD8+EMIFN-γ+/
Th17 (Supplementary Figure 3B), and CD8+CMIFN-γ+/Th17 
(Figure S3C in Supplementary Material) ratios were negatively 
correlated with the degree of tapering.
Of 14 whole tapering patients, 4 patients were successfully 
tapered to 0% dosage of immunosuppressive drugs. As we 
mentioned above, three patients were tolerance group (group 1) 
patients. The other one patient was in re-tapering group (group 
3) which is one of non-regulation group, because he had experi-
enced nontolerance at the dose of 0%. The Treg/Th17 ratio was 
increased in both these groups, but in tolerance group (group 
1) was more consistent and higher than in re-tapering group 
(group 3) (Figure S4A in Supplementary Material). The Th1/Th17 
ratio showed similar alterations in both groups with a slightly 
higher ratio in group 1, especially at 50% dosage (Figure S4B in 
Supplementary Material). The CD8+EMIFN-γ +/Th17 ratio also 
demonstrated similar changes in both groups with a higher ratio 
in group 1 (Figure S4C in Supplementary Material). The changes 
in the CD8+CMIFN-γ+/Th17 ratio were similar to but not as clear 
as those in the Treg/Th17 ratio. The greatest difference between 
the two groups was found at 50% dosage, where group 1 demon-
strated a higher ratio than group 3 (Figure S4D in Supplementary 
Material).
Figure 3 | Changes in T regulatory cell (Treg)/T helper 17 (Th17) cell ratio as immunosuppressive drug doses are tapered (n = 14). (a) There has been a moderate 
positive correlation between dose reduction and Treg/Th17 (ρ = 0.586, P < 0.001). (B) The Treg/Th17 ratio between regulation and non-regulation groups during 
tapering of immunosuppressive drug doses. (c) The Treg/Th17 ratios in the regulation and non-regulation groups after 50% reduction of immunosuppressive drugs 
(**P < 0.03). (D) The comparison of changing in Treg/Th17 ratio between group 1 and group 2 which are sub-groups of regulation group during tapering of 
immunosuppressive drugs. (e) The changing of Treg/Th17 ratio in all four groups. (F) The Treg/Th17 ratio of four groups at 50% reduction of immunosuppressive 
drugs. Group 1 had the highest Treg/Th17 ratio than that of other three groups.
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Differences in histopathologic Findings  
in regulation and non-regulation groups
In regulation group, two patients who were subclassified into 
group 1 (tolerance group) agreed to undergo liver biopsy. Four 
patients in non-regulation group agreed to take liver biopsy. In 
the regulation group, the biopsies showed mild portal inflam-
mation, but in the non-regulation group, there was moderate 
portal inflammation and even vasculitis in the liver tissues that 
were biopsied at the time of rejection (Figure  5A). We also 
observed an alteration in the ratio of IL-17 and Foxp3 in liver 
tissue. IL-17 expression was also increased in liver tissue from 
the non-regulation group compared with that of the regula-
tion group (P = 0.003, Figure 5B). However, Foxp3 expression 
was decreased in liver tissue from the non-regulation group com-
pared with that of the regulation group (P = 0.046, Figure 5C).
representative Flow chart of 60 Months 
Follow-up in each group
The data at the 60-month follow-up for each group are shown in 
Figure 5. In tolerance group (group 1) patient, 30 months was 
taken to taper the immunosuppressive drug doses and there was 
no significant increases in liver enzymes for the whole 60 months. 
Immunologic markers were maintained at increased levels dur-
ing follow-up even after complete tapering/discontinuation of 
immunosuppressive agents (Figure  6A). These increased ratio 
of immunologic markers in tolerance group was quite higher 
Figure 4 | Changes in T helper (Th)1/Th17 cell, CD8EM+interferon(IFN)-γ+/Th17, and CD8CM+IFN-γ+/Th17 ratio as immunosuppressive drug doses are tapered 
(n = 14). (a) Th1/Th17 ratio of the regulation group increased, but that of the non-regulation group did not increase more. (B) At 50% of immunosuppressive drug 
dosage, Th1/Th17 ratio of regulation group increased compared with that of non-regulation group (*P < 0.05). (c) CD8EM+IFN-γ+/Th17 ratio of the regulation group 
had been more increased than that of non-regulation group. (D) At 50% dosage, the increase in the CD8EM+IFN-γ+/Th17 ratio was higher in regulation group than 
non-regulation group without significance. (e) CD8CM+IFN-γ+/Th17 ratio of the tolerance group increased, but that of the non-regulation group decreased. (F) The 
comparison of the CD8CM+IFN-γ+/Th17 ratio at 50% dosage between regulation and non-regulation group.
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and remarkable than that of other 3 groups. Minimization group 
(group 2) demonstrated no increase in liver enzymes and a 
smaller increase in Treg/Th17 and Th1/Th17 ratios than tolerance 
group (Figure 6B). The re-tapering group (group 3) patient who 
had experienced nontoleracne at 50% tapering was re-tapered 
after recovery from the rejection episode. During the tapering 
process, his immunologic markers did not increase as much as 
those of groups 1 and 2. At the time of the rejection episode, the 
immunologic markers had decreased; during the re-tapering 
and follow-up periods, the immunologic markers showed a 
fluctuation with sustained mild increases (Figure 6C). However, 
in the no re-tapering group (group 4), there were no increase in 
immunologic markers including Treg/Th17 during tapering or 
rejection episodes and follow-up (Figure 6D).
DiscussiOn
In this prospective pilot study, we identified potential immune 
markers, particularly the Treg/Th17 ratio, for prediction of opera-
tional tolerance during immunosuppressive drug dose tapering 
Figure 5 | Comparison of histopathologic findings in regulation and non-regulation groups. Two patients in the regulation group and four patients in the non-
regulation group agreed to undergo liver biopsy. (a) Only mild portal inflammation was found in liver tissue from the regulation group. In contrast, moderate portal 
inflammation and even vasculitis was detected in liver tissue from the non-regulation group. (B,c) Biopsy tissues were stained with antibodies specific for IL-17  
and Foxp3. Brown staining indicates positive for IL-17 and Foxp3, and positive cells are pointed with thin arrow. The number of positive cells was counted in 
six-independent liver tissues. (B) Regulation group n = 2, Non-regulation group n = 4, P = 0.003 C. Regulation group n = 2, Non-regulation group n = 4, P = 0.046.
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in long-term stable LT recipients. We documented that the ratio 
of Treg/Th17 increased much more in regulation patients than 
in non-regulation patients during tapering of immunosuppres-
sive drug treatment. Moreover, the Treg/Th17 ratio remained 
increased over the 60-month follow-up in tolerant patients.
The rate of operational tolerance in our study was about 21% 
(3/14). This result is similar to those of previous studies that 
suggested rates of operational tolerance from 5 to 50% (1–3). 
All the non-regulation (nontoleracne) patients (n = 7) in the 
tapering group recovered after tapering was stopped and the 
dosage of immunosuppressive drugs was increased. This result 
was consistent with that of a previous study (2). Evaluation of 
the time at which rejection occurred showed that it manifested 
at an average immunosuppressive drug dose of 29.0 ±  17.6% 
(0–50%) of the initial dose and more than 12 months after ini-
tiating tapering. In a previous study in children, rejection was 
documented at a dose of 38.4 ± 26.9% (0–75%) (2). Comparison 
of the clinical parameters of the regulation and non-regulation 
groups showed that group 4 patients had a shorter time, since 
LT, although this was not significant. Time since transplanta-
tion is the only established clinical factor associated with 
tolerance. Recipients with a longer time since LT had a higher 
tolerance rate than those with shorter times since LT (22). 
In our study, although the difference was not significant, the 
shorter time since LT in the group 4 could have contributed to 
their nontolerance.
The most meaningful finding of this research is that the ratio 
of Treg/Th17 in PBMCs can be used to predict tolerance after 
LT. We demonstrated that the Treg/Th17 ratio increased as the 
immunosuppressive drug doses were reduced. Moreover, the 
Treg/Th17 ratio increased much more with tapering in the regula-
tion group than in the non-regulation group. The non-regulation, 
especially group 4, demonstrated decreased Treg/Th17 ratios as 
tapering progressed from 75 to 50% of the initial drug dose. These 
findings are consistent with those of Pons et  al. who reported 
that Treg cells increased in tolerant patients (23), but contrast 
with those of García et al. who reported that Treg cells were not 
altered in tolerant patients (24). Our finding that the Treg/Th17 
ratio decreased in the non-regulation group (groups 3 and 4) 
also could be explained by the previous report suggesting that 
Th17 cells are a critical marker of acute rejection after LT (25). 
In our study, tolerant patients (group 1) maintained consistently 
high Treg/Th17 ratios until complete withdrawal of immuno-
suppression. Thus, operational tolerance may be predicted by 
Figure 6 | Representative 60-month flow chart of all four groups. The gray bar means the dosage of immunosuppressive drugs at the time of each tapering time. 
(a) In tolerant group (group 1) patients, immunosuppressive drug treatment was discontinued over a period of 30 months and there was no significant increase in 
liver enzymes for the whole 60 months. Immunologic markers were maintained at an increased level. (B) Minimization group (group 2) demonstrated no increase in 
liver enzymes and smaller increase in T regulatory (Treg)/T helper 17 (Th17) cell and Th1/Th17 compared with group 1. (c) The re-tapering group (group 3) patient 
experienced rejection at 50% of the initial immunosuppressant dose. After recovery his immunosuppressive drug doses were re-tapered. During retapering, his 
immunologic markers were sustained at increased but fluctuating levels. (D) The no re-tapering group (group 4) patients experienced rejection at 20% of the initial 
immunosuppressant dose and recovered after increasing the dose to the initial amount. There was no increase in immunologic markers including Treg/Th17 during 
follow-up while taking the initial dose of immunosuppressive drugs.
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checking the changes in the ratio of Treg/Th17 in blood. To our 
knowledge, this is the first study to suggest that the reciprocal 
balance between Th17 and Treg in the peripheral blood of LT 
recipients is correlated with immune tolerance. These results also 
suggest that immunosuppressive drug treatment can inhibit the 
development of tolerance in LT recipients.
Interferon-γ, which is expressed by Th1 and CD8+ T cells, is an 
important cytokine for allograft survival. It is well documented 
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that IFN-γ deficiency induces rejection in experimental LT (26). 
It has been suggested that activation of CD8+EM T cells through 
the T-cell antigen receptor and the costimulatory receptor CD28 
induces rapid IFN-γ expression (27). Currently, IFN-γ can 
regulate necroptosis and loss of IFN-γ aggravated experimen-
tal autoimmune disorder through upregulation of Th17  cells 
differentiation (28). Since, necroptosis has been observed in 
liver-related injury and disease indicating that necroptosis can 
be a target of the pathogenesis of several liver diseases (29, 30), 
induction of IFN-γ level can improve inflammatory response. In 
this study, we found that the Th1/Th17 and CD8+EMIFN-γ+/Th17 
ratios were increased in the tapering groups. These results suggest 
that tapering can induce tolerance by increasing the number of 
cells releasing IFN-γ.
With respect to histopathology, although only a few patients 
underwent liver biopsies, the regulation group showed less 
portal inflammation than the non-regulation group. Our results 
are consistent with those of a previous study in children show-
ing that the tolerant group maintained stable histology during 
a 5-year follow-up after withdrawal of immunosuppressive 
drugs (31). Moreover, we detected that IL-17 expression was 
enhanced, whereas Foxp3 expression was reduced in the liver 
of non-regulation patients compared with regulation patients. 
These histopathologic results were correlated with those from 
blood samples using confocal microscopy. Therefore, it is possi-
ble that the blood Treg/Th17 ratio may reflect histologic changes 
in the liver.
We also conducted a 60-month follow-up of clinical data, 
immunologic markers, and histologic findings. In tolerant 
patients with stable liver enzymes, elevated levels of immunologic 
markers including the Treg/Th17 ratio were maintained during 
the whole follow-up period. However, nontolerant patients had 
lower levels of the immunologic markers, including the Treg/
Th17 ratio. Therefore, we could speculate that high Treg/Th17, 
Th1/Th17, and CD8/Th17 ratios may contribute to not only 
establishment of tolerance, but also its continuation.
Because this was a pilot study it had several limitations. First, 
only a small number of patients underwent tapering of immuno-
suppressive drug doses. For the safety of patients, we conducted 
the tapering study in the 20% most immunologically stable 
patients who also had stable laboratory measurements and clini-
cal history. For this reason, only 14 patients underwent tapering 
of immunosuppressive drugs. Second, there were only a few 
liver biopsy samples and no baseline liver biopsies, because only 
a small number of the patients agreed to undergo liver biopsy. 
Despite these limitations, this is the first study to serially monitor 
the Treg/Th17 ratio in PBMCs from LT recipients undergoing 
tapering of immunosuppression over 60  months of follow-up 
and to compare parameters indicating immune tolerance in 
the regulation and non-regulation groups of LT recipients. This 
point is strength for the clinical application of these data to LT 
recipients.
In summary, the ratio of Treg/Th17 in PBMCs increased to a 
greater degree in tolerant patients during tapering of immunosup-
pressive drugs and after withdrawing immunosuppressive drugs. 
Our results suggest that the reciprocal balance between Th17 and 
Treg in the peripheral blood of LT recipients may contribute to 
the establishment and maintenance of tolerance and could be 
used as an indicator of the likelihood of operational tolerance in 
LT recipients.
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Figure s1 | Dosage and timing at the moment of intolerance (n = 7).
Figure s2 | Changes in Th1/Th17, CD8EM+IFN-γ+/Th17, and CD8CM+IFN-γ+/
Th17 ratio of all four groups as immunosuppressive drug doses are tapered.  
(a) Th1/Th17 ratio of group 1 increased compared with that of the other three 
groups. (B) At 50% dosage, the increase in the Th1/Th17 ratio was greatest in 
group 1 followed by group 2, group 3, and group 4. (c) Group 1 had more 
increased CD8EM+IFN-γ+/Th17 ratio than that of the other three groups.  
(D) At 50% dosage, group 1 had the greatest increase in the CD8EM+IFN-γ+/
Th17 ratio. (e) CD8CM+IFN-γ+/Th17 ratio of group 1 increased compared  
with that of the other three groups. (F) At 50% dosage, the increase in the 
CD8CM+IFN-γ+/Th17 ratio was greatest in group 1.
Figure s3 | Correlation between dosage of immunosuppressive drugs and 
Th1/Th17, CD8EM+IFN-γ+/Th17, and CD8CM+IFN-γ+/Th17 ratio as tapering 
immunosuppressive drug. (a–c) There has been mild positive correlation 
between the ratio of Th1/Th17, CD8EM+IFN-γ+/Th17, and CD8CM+IFN-γ+/ 
Th17 and dosage tapering.
Figure s4 | Changes in Treg/Th17, Th1/Th17, CD8EM+IFN-γ+/Th17,  
and CD8CM+IFN-γ+/Th17 ratio as immunosuppressive drug doses are  
tapered. (a–D) Treg/Th17, Th1/Th17, CD8EM+IFN-γ+/Th17, and CD8CM+ 
IFN-γ+/Th17 ratio of the group 1 patients had been more increased with stable 
value than that of the group 3 patients.
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